Immediate breast reconstruction in locally advanced breast cancer: is it safe? Kadhim TaqiJin-Si PaoRebecca Warburton Review 31 August 2021 Pages: 175 - 182
Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer Jasmine S. SukumarDionisia QuirogaSagar Sardesai Review 08 September 2021 Pages: 183 - 188
Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer Jason A. MouabbiC. Kent OsborneMothaffar F. Rimawi Review 13 September 2021 Pages: 189 - 201
Estrogen-regulated AGR3 activates the estrogen receptor signaling pathway to promote tamoxifen resistance in breast cancer Rui JiangYongjie SunPeng Shi Brief Communication 14 September 2021 Pages: 203 - 211
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China Xiaoran LiuAndrew A. DavisMassimo Cristofanilli Preclinical study Open access 01 September 2021 Pages: 213 - 226
Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression Tiago V. AugustoCristina AmaralGeorgina Correia-da-Silva Preclinical study 08 September 2021 Pages: 227 - 240
Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival Athina GiannoudisAlexander SartoriCarlo Palmieri Preclinical study Open access 09 September 2021 Pages: 241 - 253
Hyperglycemic conditions proliferate triple negative breast cancer cells: role of ornithine decarboxylase Caleb C. CapellenJose Ortega-RodasSurabhi Chandra Preclinical study 16 September 2021 Pages: 255 - 264
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida) Lori J. GoldsteinMauro Mansuttifor the fRida Trial Investigators Clinical trial Open access 03 September 2021 Pages: 265 - 275
Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? Xiaofang WangLi ZhangJinli Ma Clinical trial Open access 06 September 2021 Pages: 277 - 286
Medical care disruptions during the first six months of the COVID-19 pandemic: the experience of older breast cancer survivors A. DilawariK. E. RentscherThinking and Living with Cancer Study Clinical trial 13 September 2021 Pages: 287 - 293
Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer Ben P. HaynesGene SchusterMitch Dowsett Clinical trial Open access 15 September 2021 Pages: 295 - 305
Genetic testing in women with early-onset breast cancer: a Traceback pilot study Annelie AugustinssonMartin P. NilssonHans Ehrencrona Clinical Trial Open access 16 September 2021 Pages: 307 - 315
The characteristics associated with upgrade on surgical pathology of conventional imaging occult DCIS diagnosed by MRI Yoav AmitaiTehillah S. MenesVivianne A. R. Freitas Epidemiology 02 September 2021 Pages: 317 - 327
A CTL/M2 macrophage-related four-gene signature predicting metastasis-free survival in triple-negative breast cancer treated with adjuvant radiotherapy Yunfei YeJungang MaDong Wang Epidemiology 05 September 2021 Pages: 329 - 341
Fatty liver disease and changes in dense breasts in pre- and postmenopausal women: the Kangbuk Samsung Health Study Yoosun ChoYoosoo ChangSeungho Ryu Epidemiology 16 September 2021 Pages: 343 - 353
